Literature DB >> 19650793

Pirfenidone: a potential therapeutic option in the treatment of liver fibrosis.

Fabio Grizzi.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19650793     DOI： 10.1111/j.1440-1681.2009.05262.x

Source DB:  PubMed          Journal:  Clin Exp Pharmacol Physiol        ISSN： 0305-1870            Impact factor:   2.557


× No keyword cloud information.
  4 in total

1.  15th International Symposium on Cells of the Hepatic Sinusoid, 2010.

Authors:  Laurie D DeLeve; Hartmut Jaeschke; Vijay K Kalra; Kinji Asahina; David A Brenner; Hidekazu Tsukamoto
Journal:  Liver Int       Date:  2011-04-19       Impact factor: 5.828

2.  Tolerability and Pharmacokinetics of Hydronidone, an Antifibrotic Agent for Hepatic Fibrosis, after Single and Multiple Doses in Healthy Subjects: an Open-Label, Randomized, Dose-Escalating, First-in-Human Study.

Authors:  Yani Liu; Jianhong Wu; Zhongfang Li; Ying Luo; Fandian Zeng; Shaojun Shi
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2017-02       Impact factor: 2.441

3.  Suppression of TGF-β pathway by pirfenidone decreases extracellular matrix deposition in ocular fibroblasts in vitro.

Authors:  Thomas Stahnke; Bhavani S Kowtharapu; Oliver Stachs; Klaus-Peter Schmitz; Johannes Wurm; Andreas Wree; Rudolf Friedrich Guthoff; Marina Hovakimyan
Journal:  PLoS One       Date:  2017-02-23       Impact factor: 3.240

Review 4.  New Drugs for Hepatic Fibrosis.

Authors:  Liang Shan; Fengling Wang; Dandan Zhai; Xiangyun Meng; Jianjun Liu; Xiongwen Lv
Journal:  Front Pharmacol       Date:  2022-06-13       Impact factor: 5.988
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.